Global Anal Cancer Market

Anal cancer is generally a rare type of malignancy that affects the colon and rectum. Some of the symptoms associated with anal cancer include anal or rectum bleeding, a lump near the anus, pain around the anus, itching in the anus, discharge from the anus, changes in bowel habits, and others. It can be caused due to several risk factors such as human papillomavirus (HPV) infection, excessive smoking, and medical history of vaginal, cervical, or vulvar cancers.

Market Size & Growth Rate:

The anal cancer market was valued at USD 810.4 million in 2022 and is projected to reach USD 1242.9 million by 2028, with a CAGR of 7.4%. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies.

Get more details on this report - Request Free Sample

Market Dynamics:

American Cancer Society-2022, it is estimated that around 9,440 new cases of anal cancer would be reported in the U.S. by the end of 2022, wherein 6,290 anal cancer cases would be accounted by women and 3,150 cases of anal cancer would be accounted by men. The American Cancer Society also estimates that anal cancer would account for 1,670 deaths (930 women & 740 men) in the U.S. by the end of 2022

The presence of research and development activities for the treatment of anal cancer is expected to boost the market. For instance, In august 2021, the National Cancer Institute granted USD 4 million to Icahn School of Medicine (New York) for extensive research activities on anal cancer in women with HPV infections.

Market Drivers:

• Increasing prevalence of anal cancer: The Anal cancer market has significantly grown over the recent past and is expected to register rapid growth over the forecast period. For example, as per the World Health Organization (WHO), in 2020, the number of colorectal cancers of mortality of males and females of all ages was around 935,173 across the globe, which is 9.4% of total mortalities. In addition, the number of new anal cancer patients of both sexes of all ages in 2020 was around 1.9 million across the globe.
• According to American cancer society, in the last few years, the number of anal cancer cases has increased. it will be nearly 9,090 new cases in the United States. Anal cancer is uncommon in those under the age of 35 and is mostly diagnosed in older adults, with an average age in the early 60s.
• Moreover, increasing oncology research and development activities by competitors including anal cancer are the trigger to a footprint in anal cancer market trends. The government's increasing initiatives to raise public awareness about anal cancer are the primary drivers of the market.
• Increasing treatment algorithms for advanced anal cancer are provided.
• Growing incidence rates of Squamous cell carcinoma of the anal canal (SCCA)

Challenges:

The high cost of treatment and stringent regulatory scenario restrain the market growth.

• The increasing price of anal cancer treatment is expected to restrain the growth of the market
• For instance, the NCI-2022 report estimates that cancer-related direct medical costs in the US were USD 183 billion in 2015 and are projected to increase to USD 246 billion by 2030, a 34% increase based only on population growth and aging.

Adverse reactions of anal cancer therapeutics.

Competitive Landscape:

Novartis AG, AstraZeneca plc, Pfizer Inc., Merck & Co., Inc., Bayer AG, Bristol-Myers Squibb Company, AbbVie Inc., Hoffmann-La Roche Ltd., Johnson & Johnson Private Limited, Eli Lilly and Company, Atara Biotherapeutics Inc., Onconova Therapeutics, BioMimetix JV, LLC, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Sun Pharmaceutical Industries Ltd., Sanofi, and Others.

Key Developments:

Major players operating in the global anal cancer market are also focused on R&D to expand their product portfolio.

• In October 2022, The American Cancer Society (ACS) approved funding for 89 new Extramural Discovery Science (EDS) research grants totaling USD 54.3 million. It will fund investigators at 65 institutions across the United States from January 1, 2023.?
• In June 2021, Bristol Myers Squibb received European Commission Approval for Opdivo plus Yervoy to treat patients of anal cancer and it has received marketing authorizations across the European region.
• In November 2021, Pfizer Company acquired Trillium Therapeutics for approximately USD 2.22 billion, to boost its oncology portfolio with the addition of next-generation immune therapies.
• In December 2021, SQZ Biotechnologies Company reported that its investigational therapy induced radiographic, symptomatic, and immune response as monotherapy in the post-checkpoint HPV solid tumor patient
• In June 2020, Merck & Co. received FDA approval for GARDASIL 9 (Human Papillomavirus 9-valent, Recombinant vaccine) to the treatment of anal cancer, cervical, vaginal, and other cancers linked to HPV
• In September 2020, Incyte Company announced positive phase II clinical trials results for the efficacy and safety of its novel immunotherapy using Retifanlimab for the treatment of advanced squamous cell carcinoma
• In July 2019, Incyte collaborated with Zai Lab Ltd, company for the development and commercialization of its investigational monoclonal antibody, and INCMGA0012 for the treatment of anal cancer

Regional Analysis:

North America: The increasing prevalence of anal cancer diseases, growing extensive research and development activities in the latest tools & techniques, novel therapeutic solutions for the treatment of anal cancer, and rising adoption of acquisitions, collaborations, and growing funds by several public & private sectors performing in the anal cancer platform, are the significant factors that are anticipated to propel the growth of the anal cancer market over the forecast period.

As per the American Cancer Society, around 9,090 new cases of anal cancer are anticipated in the US in 2021, of which 6,070 are in women and 3,020 in men. In addition, around 1,430 mortalities of anal cancer are anticipated in 2021. Moreover, around 104,270 new cases of colon cancer and around 45,230 new cases of rectal cancer are anticipated in the US in 2021

Europe holds the second-largest share of the anal cancer market due to the rising prevalence of anal cancer and the presence of significant market key competitors. owing the historic forecast period, nearly 1,500 new cases of anal cancer are recorded every year in the U.K. and nearly 25 out of 100 people (approximately 25%) diagnosed with anal cancer each year in the UK are aged 75 and over, more common in women than men, according to the Cancer Research U.K

Asia-Pacific is predicted to be the fastest-growing regional market and is anticipated to hold a considerable market share in the global anal cancer market. The rising geriatric population which is prone to cancer and the increasing incidence and prevalence rate of anal cancer are the factors that are growing the market demand in the region.

As per the report of WHO, in 2020, in the Asia-Pacific region, around 569,200 incidences of anal cancer were recorded, which is 49.6% of total cases across the globe. The expanding cancer awareness and a large patient pool of sexually transmitted diseases, which is more prone to anal cancer are other factors driving the market growth, especially in developing countries.

Middle East: Healthcare including the anal cancer market in the MEA gaining significant progress on account of various factors including government initiatives to encourage medical tourism, evolving health insurance policies, and growing propensity among the local population to consume digital health services. The anal cancer market is primarily dominated by five countries such as Saudi Arabia, Iran, Israel, Egypt, and UAE. Moreover, all together they cover more than 85% of the Middle East healthcare market.

Latin America has contributed to the poor growth in the leukemia market, due to a lack of approved treatment options, insubstantial low infrastructure in healthcare platforms, along with a lack of awareness about the impacts of epilepsy on the quality of life of the affected, is hindering the prospects

Market Segmentation:

The global Anal cancer market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Drug Type

• Fluorouracil
• Cisplatin
• Carboplatin
• Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)

The global Anal cancer market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Cancer Type

• Squamous Cell Carcinoma
• Carcinoma In-situ
• Adenocarcinoma
• Basal Cell Carcinoma
• Melanoma

The global Anal cancer market estimates (Value USD Million) & Forecasts and Trend Analyses, 2022 to 2027 based on Treatment

• Chemotherapy
• Radiation Therapy
• Immunotherapy
• Surgery

What is the Anal Cancer Market Report about?

The anal cancer market report discusses the commercial and clinical activity associated with applications. It provides insights on the total size of the potential opportunity, key segments driving growth, key challenges faced, and a thorough analysis of market competition by product, geography, indication, and forecasts through 2027. Detailed coverage of the approved anal cancer, including regulatory approvals, pricing, reimbursement, and market penetration. So, a new investor can potentially gain information about anal cancer therapeutic companies, their key products, their core strategy, key trends in the anal cancer market, and more.

The anal cancer market report is essential for all stakeholders including research companies, manufacturing companies, distribution companies, government agencies, and others.

• Capitalize on rapidly emerging trends
• Optimize decision-making
• Reduce company risk
• Approach partners/investors for collaboration or funding
• Implement an informed and advantageous business strategy in 2022
• Detailed coverage of the approved nuclear medicine therapeutics, including regulatory approvals, pricing, reimbursement, and market penetration
• Profiles of leading & upcoming anal cancer competitors composing the global marketplace